SOPHiA GENETICS SA announced that the company is reaffirming its previously provided guidance of: full-year reported revenue growth expected to be at or above 30%; full-year constant currency revenue growth excluding COVID-19-related revenue expected to be between 30% and 35%; and 2023 operating losses expected to be below 2022 levels.